NEW YORK, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against GoodRx Holdings, Inc. (NASDAQ: GDRX) on behalf of long-term stockholders following a class action complaint that was filed against GoodRx on April 22, 2024 with a Class Period from September 23, 2020, to November 8, 2022. Our investigation concerns whether the board of directors of GoodRx have breached their fiduciary duties to the company. ...

It was a mixed bag of growth and challenges for digital healthcare platform GoodRx during the second quarter. In reporting its second-quarter results Thursday (Aug. 8), GoodRx said monthly active users (MACs) rose 8%, contributing to a 7% rise in prescription transactions revenue, which totaled $146.7 million. While overall second-quarter revenue rose 6%, to $200.6 million, subscription revenue sank 8%, to $22 million, driven by a decrease in the number of subscription plans due to last month's sunsetting o ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ________________________________ FORM 10-Q ________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______. | --- | --- | |-------------------------------------------- ...

GoodRx Holdings, Inc. (NASDAQ:GDRX) Q2 2024 Earnings Conference Call August 8, 2024 8:00 AM ET Company Participants Aubrey Reynolds - Director of Investor Relations Scott Wagner - Interim Chief Executive Officer Karsten Voermann - Chief Financial Officer Mike Walsh - President & EVP, Prescription Marketplace Conference Call Participants Charles Rhyee - TD Cowen Lisa Gill - JPMorgan John Ransom - Raymond James Stephanie Davis - Barclays Jailendra Singh - Truist Securities Scott Schoenhaus - KeyBanc Stan Bere ...

GoodRx Holdings, Inc. (GDRX) reported $200.61 million in revenue for the quarter ended June 2024, representing a year-over-year increase of 5.8%. EPS of $0.08 for the same period compares to $0.07 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $200.68 million, representing a surprise of -0.03%. The company delivered an EPS surprise of -11.11%, with the consensus EPS estimate being $0.09. While investors closely watch year-over-year changes in headline numbers -- revenue and ear ...

GoodRx Holdings, Inc. (GDRX) came out with quarterly earnings of $0.08 per share, missing the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.07 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -11.11%. A quarter ago, it was expected that this company would post earnings of $0.09 per share when it actually produced earnings of $0.08, delivering a surprise of -11.11%. Over the last four quarters, th ...

Exhibit 99.1 GOODRX REPORTS SECOND QUARTER 2024 RESULTS SANTA MONICA, Calif. -- ( August 8, 2024 ) -- GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," "GoodRx," or the "Company"), the leading prescription savings platform in the U.S., has released its financial results for the second quarter of 2024. Second Quarter 2024 Highlights • Revenue1 and Adjusted Revenue1 of $200.6 million • Net income of $6.7 million; Net income margin of 3.3% • Adjusted Net Income1 of $32.4 million; Adjusted Net Income Mar ...

The upcoming report from GoodRx Holdings, Inc. (GDRX) is expected to reveal quarterly earnings of $0.09 per share, indicating an increase of 28.6% compared to the year-ago period. Analysts forecast revenues of $200.68 million, representing an increase of 5.8% year over year. The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period. ...

VISIGN Upside Potential On the upside potential, GoodRx could sign a major corporate or insurance partner similar to the Kroger deal that would provide a pool of continuous customers. This would have to go hand in hand with strong execution on all current strategies, as they need to double the market and then grow on top of that. As discussed above, upside potential is mitigated by industry headwinds that I don't believe management has fully considered in the long-term guidance range. I am updating my analy ...

First biosimilar with an exclusive low cash price on the GoodRx platform RIDGEFIELD, Conn. and SANTA MONICA, Calif., July 18, 2024 /PRNewswire/ -- Boehringer Ingelheim and GoodRx (Nasdaq: GDRX), the leading prescription savings platform in the U.S., announced today a patient affordability initiative to provide citrate-free Adalimumab-adbm, Boehringer's biosimilar to Humira® (adalimumab), at a low cash price available exclusively on GoodRx. This program is a significant step in addressing access and affordab ...